



**FOR IMMEDIATE RELEASE: 2021/4/23**

Listed Name: M3, Inc.  
(TSE Section 1 Ticker Code: 2413)  
(<https://corporate.m3.com/en>)  
Headquarters: 1-11-44 Akasaka, Minato-ku, Tokyo  
Representative: Itaru Tanimura, Representative Director  
Contact: Eiji Tsuchiya, Director  
Phone: 03-6229-8900 (main line)

**Notice Concerning Differences Between Actual Consolidated and Non-consolidated Results for the Fiscal Year Ended March 31, 2021 versus the Respective Previous Fiscal Year**

This notice serves to provide information regarding the difference between actual consolidated and non-consolidated results for the fiscal year ended March 31, 2021 and the respective results for the fiscal year ended March 31, 2020.

**1. Differences between actual consolidated results for the fiscal year ended March 31, 2021 and the fiscal year ended March 31, 2020 (IFRS)**

	Net Sales	Operating Profit	Pre-Tax Profit	Net Profit	Profit Attributable to Owners of the Parent
Actual results for fiscal year ended March 31, 2020 (A)	Millions of Yen 130,973	Millions of Yen 34,337	Millions of Yen 34,610	Millions of Yen 24,153	Millions of Yen 21,635
Actual results for fiscal year ended March 31, 2021 (B)	169,198	57,972	58,264	41,198	37,822
Difference ( B – A )	+38,225	+23,635	+23,655	+17,045	+16,187
Difference ( % )	+29.2	+68.8	+68.3	+70.6	+74.8

**2. Reason of Differences**

The consolidated actual results for the fiscal year ended March 31, 2021 were notably exceeded the results from the previous year mainly due to the growth of Medical Platform businesses, impacted by a sharp surge in demand from pharmaceutical companies in response to the COVID-19 pandemic, as well as the sales and profit growth in Overseas businesses, despite temporary decreases in demand across the Evidence Solution and Career Solution businesses.



**3. Differences between actual non-consolidated results for the fiscal year ended March 31, 2021 and the fiscal year ended March 31, 2020 (J-GAAP)**

	Net Sales	Operating Profit	Ordinary Profit	Profit
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen
Actual results for fiscal year ended March 31, 2020 (A)	27,012	13,548	17,730	12,232
Actual results for fiscal year ended March 31, 2021 (B)	49,911	28,031	30,781	21,994
Difference ( B – A )	+22,899	+14,483	+13,051	+9,762
Difference ( % )	+84.8	+106.9	+73.6	+79.8

**4. Reason of Differences**

The actual non-consolidated results for the fiscal year ended March 31, 2021 were notably exceeded the results of the previous year mainly driven by a sharp surge in demand from pharmaceutical companies in response to the COVID-19 pandemic.